Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.4K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.4K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of sleep, sedentary behavior, and physical activity with incident migraine: a prospective cohort study.

BMC public health·2026
Same author

Challenges and Opportunities: Nanomaterials in Epilepsy Diagnosis.

ACS nano·2025
Same author

Low pulse pressure and high serum complement C1q are risk factors for hemodialysis headache: A case-control study.

Headache·2024
Same author

The Role of Circadian Rhythm in Neurological Diseases: A Translational Perspective.

Aging and disease·2023
Same author

A new experimental rat model of nocebo-related nausea involving double mechanisms of observational learning and conditioning.

CNS neuroscience & therapeutics·2023
Same author

Aryl hydrocarbon receptors improve migraine-like pain behaviors in rats through the regulation of regulatory T cell/T-helper 17 cell-related homeostasis.

Headache·2023

Related Experiment Video

Updated: Apr 15, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K

Epilepsy: Molecular Pathogenesis and Emerging Therapies.

Wanbin Huang1,2, Jiabin Zong3, Yu Zhang1,2

  • 1Department of Neurology Renmin Hospital of Wuhan University Wuhan Hubei China.

Medcomm
|April 14, 2026
PubMed
Summary

Epilepsy affects many, with one-third resistant to antiseizure medications (ASMs). This review explores molecular causes and novel treatments like gene therapy for better seizure control.

Keywords:
clinical trialseffect evaluationemerging therapyepilepsymolecular pathogenesisprecision medicine

More Related Videos

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.6K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

4.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.6K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

4.1K

Area of Science:

  • Neurology
  • Molecular Biology
  • Pharmacology

Background:

  • Epilepsy is a common neurological disorder with significant societal impact.
  • Approximately one-third of patients develop drug-resistant epilepsy despite multiple antiseizure medications (ASMs).
  • Current treatments, including surgery, are underutilized or insufficient for many.

Purpose of the Study:

  • To systematically review advances in understanding epilepsy's etiology and molecular pathogenesis.
  • To identify novel therapeutic targets and evaluate emerging treatments for epilepsy.
  • To provide a framework linking molecular mechanisms to therapeutic applications for improved epilepsy management.

Main Methods:

  • Systematic review of preclinical and clinical studies on epilepsy.
  • Analysis of molecular pathogenesis and etiological factors.
  • Evaluation of emerging therapeutic strategies including novel ASMs, surgery, neurostimulation, focused ultrasound, nanomedicine, cell therapy, and gene therapy.

Main Results:

  • Advances in understanding molecular pathogenesis have revealed diverse therapeutic targets.
  • Emerging therapies show potential for long-term seizure control in drug-resistant epilepsy.
  • Integration of preclinical and clinical findings highlights promising innovative approaches.

Conclusions:

  • Novel therapeutic strategies derived from molecular insights offer hope for improved epilepsy treatment.
  • Further research is crucial to overcome current limitations and enhance treatment precision.
  • This review bridges molecular mechanisms and therapeutic applications, advancing precision epilepsy care.